Please assess the completion status of the following clinical trial:

Trial Title: Safety of N-acetylcysteine in Maternal Chorioamnionitis (NAC in Chorio)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE1/PHASE2
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Participants had all of the following to qualify:~* Chorioamnionitis, defined as either 1) clinical diagnosis of choriomanionitis 2) maternal fever greater than or equal to 100 degrees F in the presence of rupture of membranes or 2 of the following: uterine tenderness, maternal WBC \> 15,000 cells/mm, fetal tachycardia \> 160 bpm, malodorous amniotic fluid, or in preterm group only, rupture of membranes and active preterm labor.~* Gestational age ≥ 24 completed weeks, by first trimester ultrasound or date of last menstrual period.~* No greater than 4 hours from onset of fever or diagnosis.~Exclusion Criteria:~Participants had none of the following:~* Asthma, steroid-dependent~* Clinical sepsis, whether viral or bacterial in nature, defined as fever with signs of cardiovascular compromise in mother (blood pressure \< 90/50, heart rate \> 120 bpm, need for oxygen due to maternal saturations below 92%, pneumonia, pyelonephritis, or meningitis)~* Seizure disorder~* Fetal weight or biparietal diameter less than the 10th% for gestational age~* Suspected major genetic or congenital abnormality~* Fetal distress which demands immediate delivery (poor fetal biophysical profile, late decelerations, sinusoidal fetal heart rate pattern)~* Participation in another therapeutic clinical trial

- Gender: ALL
- Minimum Age: 13 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- N-acetylcysteine (Type: EXPERIMENTAL): Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.
- Control (Type: ACTIVE_COMPARATOR): Mother/infant pairs were stratified by gestational age into premature (P) and term (T) cohorts.

Based on this trial design, predict the completion outcome and termination type (if applicable).